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Abstract
Background and objectives Patient and public involvement (PPI)
is seen as a way of helping to shape health policy and ensure a
patient-focused health-care system. While evidence indicates that
PPI can improve health-care decision making, it also consumes
monetary and non-monetary resources. Given the ﬁnancial cli-
mate, it is important to start thinking about the costs and beneﬁts
of PPI and how to evaluate it in economic terms.
Design We conducted a literature review to assess the potential
beneﬁts and costs of involvement and the challenges in carrying
out an economic evaluation of PPI.
Results The beneﬁts of PPI include eﬀects on the design of new
projects or services, on NHS governance, on research design and
implementation and on citizenship and equity. Economic evalua-
tion of PPI activities is limited. The lack of an appropriate analyti-
cal framework, data recording and understanding of the potential
costs and beneﬁts of PPI, especially from participants’ perspec-
tives, represent serious constraints on the full evaluation of PPI.
Conclusions By recognizing the value of PPI, health-care providers
and commissioners can embed it more eﬀectively within their orga-
nizations. Better knowledge of costs may prompt organizations to
eﬀectively plan, execute, evaluate and target resources. This should
increase the likelihood of more meaningful activity, avoid token-
ism and enhance organizational eﬃciency and reputation.
Introduction
The emphasis on patient and public involve-
ment (PPI), sometimes known as ‘patient and
public engagement’, in diﬀerent aspects of
health-care activity in the UK and internation-
ally has increased in the last decade.1–5 This is
seen as key to health-care reform, helping to
shape health policy and ensure a patient-
focused health-care system.6–8
While there has been extensive participatory
activity in the NHS, there is limited knowledge
about its impact.9–11 The international research
evidence base underpinning PPI remains partial
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and lacks consistency, and the focus on costs is
limited.1,12 While better evidence is needed to
improve practice in PPI, this needs to be bal-
anced against the costs of doing nothing –
potentially poorly designed and inappropriately
utilized health services, with sub-optimal out-
comes for patients.13 Failing to take full
account of legislation, policy and practice guid-
ance may also lead to unforeseen costs associ-
ated with judicial reviews and public inquiries.
Analytical frameworks to help service manag-
ers systematically assess both the costs and ben-
eﬁts of PPI could help. They may support them
in planning and documenting their activities, so
they can more rigorously capture the value of
PPI to their service. The way in which people
perceive the beneﬁts and costs of involvement in
PPI can diﬀer, and this has a large impact on
their willingness to take part.14 A better under-
standing of the real beneﬁts and costs would
reduce barriers to participation and increase
incentives for people to be involved.15
This paper proposes a framework for evalu-
ating the costs of PPI from both an organiza-
tional and participant perspective.
Evaluating the benefits of PPI: lack of
appropriate analytical framework
The language of PPI is frequently contested,
making it diﬃcult to establish clear aims and
objectives when planning, delivering and evalu-
ating activity.5,16 Broadly, PPI involves ‘working
together to promote and support active PPI in
health and health care and to strengthen their
inﬂuence on health-care decisions, at both the
individual and the collective level’.17 Another
view sees it in terms of the ways patients and
public draw on their experience and inﬂuence the
development and delivery of health services.11
Both Coulter and Tritter draw attention to
the diversity of approaches, determined partly
by the overall aim or goal of involvement. In
the NHS, the emphasis is often more on the
development of structures and mechanisms for
PPI than a focused task or purpose around
which activity can be appropriately planned.17
Lessons from involvement in other public
services are helpful in understanding that there
is no single eﬀective approach but a range of
methods that need to be selected and applied
based on the resources available and linked to
a deﬁned and transparent aim.18
A more rigorous approach to PPI could help
us to better understand its value. There is
much to be gained from working closely with
patients, but this must be aligned to improve-
ment in services and outcomes.17,19–22
There is only limited debate about where
resources should be invested and whether this
investment provides an immediate or sustain-
able return. Public and patient involvement is
diﬃcult to value in economic terms for a num-
ber of reasons. The variety of approaches, dif-
ferences in objectives, and distinctions between
individual and collective perspectives on its
beneﬁts all present practical diﬃculties. One
problem from a ﬁnancial and economic per-
spective is that the process of engagement by
patients and the public is seen as equally
important as the outcomes. This is because it
oﬀers insight into the views and perceptions of
others, and more potential for changing orga-
nizational culture.5 However, these beneﬁts are
much less tangible and easier to understand.
The ﬁndings from a systematic review by
Crawford et al. (2002) support the notion that
involving patients has contributed to changes
in the provision of services across a range of
diﬀerent settings. Nevertheless, the same study
shows that evidence for the eﬀects on use of
services, quality of care, satisfaction or health
of patients does not exist.23
Although it is relatively easy to identify the
beneﬁts of participation in general terms, there
is very little detailed analysis of these, with
beneﬁts largely assumed or taken for granted.24
This can lead to problems in the design and
conduct of PPI.2 Poorly conducted participa-
tion can lead to a lack of trust among partici-
pants and a loss of reputation for an
organization.25 A lack of clarity around the
objectives of PPI can result in confusion or
risks alienating the people involved if expecta-
tions are not managed, increasing costs or
leading to sub-optimal decisions.26
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In developing an analytical framework, tra-
ditional economic analysis methods were ﬁrst
examined to assess their applicability to PPI.27–
30 Many disciplines, including political science,
social science, community development and
international development, provide useful per-
spectives on the costs and beneﬁts of participa-
tion within their own ﬁeld.31 However, PPI
does not typically lend itself to traditional or
commonly used methods in economic evalua-
tion, which on their own are inadequate for
capturing all the potential beneﬁts and would
provide only limited insight for much eﬀort
(see Table 1).
To develop a suitable evaluation framework
for PPI, we need to start exploring which are
the potential beneﬁts, risks and cost of involve-
ment. Several instruments have been developed
to measure ‘patient centeredness’, but these are
unable to provide enough focus on involve-
ment because they attempt to cover so many
dimensions.24
Benefits and risks of public involvement
Although most beneﬁts cannot be ‘translated’
into straightforward monetary measures, it is
important to be aware of the beneﬁts that PPI
may deliver. A literature review suggests there
are diﬀerent types of beneﬁts arising from
PPI,37–40 that we summarize in the following
groups:
1. The eﬀects on NHS governance and legiti-
macy;
2. The eﬀects on research design and imple-
mentation;
3. The eﬀects on eﬃciency in the design and
quality of projects;
4. The eﬀects on participants and citizenship
(the so called ‘feel good’ eﬀect);
5. The eﬀects on equity issues.
Our focus in this paper is on the eﬀects of
PPI on improving health services, and we con-
centrate here on the last three of these groups.
Effects of PPI on efﬁciency in the design and
quality of projects
By incorporating information about needs, pri-
orities and capabilities of local people, PPI can
help ensure more appropriate decisions about
resource allocations and help ensure services
are adapted to local needs and wishes.41 This
can engender a sense of ownership and reduce
costs by promoting optimal use of services.
People are more likely to be informed if they
are involved, increasing their understanding of
a decision and the probability of its successful
implementation.42 Involvement can also raise
the enthusiasm of staﬀ, and leading to a more
productive working environment and better
quality outcomes.43 Greater public involvement
in decisions makes it more likely that a project
Table 1 Economic evaluation methods and their limits in
patient and public involvement (PPI) evaluation
It is difﬁcult to express outcomes of PPI in a single
quantiﬁable measure of effectiveness or utility, or to
capture the range of outcomes generated by PPI within a
single measure when there are numerous and
heterogeneous effects involved. It is unlikely that
outcomes of PPI can be translated into the type of single
monetary, effectiveness or utility measures required by
traditional methods of economic evaluation, and attempts
to do so would be complex and contentious*:
• Cost-minimization focuses primarily on costs, comparing
the costs of programmes with broadly similar outcomes. It
has insuﬃcient focus on outcomes to be of use to PPI and
it is not appropriate to value participation activities.27,28
• Cost-benefits analysis measures both costs and beneﬁts
in monetary terms and would require the translation of
beneﬁts into purely monetary metrics.
• Cost-effectiveness compares programmes costs per unit
of outcome produced, where outcomes are measured on
a single scale.27,29 This method allows comparison of
competing programmes using a single outcome measure
(such as an odds-ratio for surviving a disease) and
provides evidence for which one should be funded.
• Similarly, cost-utility analysis condenses all beneﬁts into
one generic measure of utility (such as a quality-
adjusted life year, or QALY, for a patient).29
• There are many methods expressly designed for captur-
ing non-market values, including production function,
hedonistic pricing, stated preference (contingent valua-
tion and choice modelling), balanced scorecard and
social return on investment. However, none of these are
appropriate for valuing the beneﬁts of PPI.32–36
*For example, it would be very difﬁcult to capture the monetary
value of outcomes such as ‘democracy’, ‘legitimacy’ or ‘social
cohesion’.32
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will be sustained.42 Moreover, PPI has the
potential to stimulate the development of new
ideas and innovative approaches and solu-
tions.41,44
Effects of PPI on participants and citizenship:
the ‘feel good factor’
People involved in decisions about matters
aﬀecting their own lives conﬁrm that they are
valuable and valued members of society and
can contribute in an active way.45,46 Being
active participants in an area of public life,
such as health care, can encourage people to
participate in other areas, such as the environ-
ment.45 Public involvement helps to raise
awareness and increase understanding of public
institutions and the way they work, enabling
people to better access the services they need,
and to understand the boundaries and limita-
tions of diﬀerent public bodies. It obliges peo-
ple to think more carefully about their
preferences and priorities, and about their val-
ues and beliefs, and to temper these in the light
of public debate.2,12 By participating, people
contribute to a greater sense of social integra-
tion, social cohesion and solidarity.46–48
Effects of PPI on equity
Public participation has an impact in terms of
equity. It can bring diverse and sometimes hos-
tile communities together, incorporating ‘hard
to reach’ and ‘disadvantaged’ groups into dis-
cussions, building relationships between diﬀer-
ent communities and social groups,
strengthening and creating new networks that
enable diﬀerent interests to work together.
Marginalized and excluded groups can be given
a voice, reducing the risk that some interests
are over-represented. This helps to create
greater equality of access to policy and deci-
sion-making processes. Participation increases
equity in achieving a balance across diﬀerent
interests groups and ensuring that all needs are
expressed and met. This should secure higher
equity not only when services are designed, but
also when people access the services.
Risks of PPI
Despite the generally positive view of participa-
tion, there is concern that it might be an
expensive waste of time and money and might
increase the risk of pressure from speciﬁc inter-
est groups.49,50 According to Burton, it is a
serious mistake to presume that more partici-
pation is necessarily better because2
1. The involvement of large numbers of people
can lead to overenthusiasm, without meeting
people’s expectations;
2. Poorly conducted participation can be expen-
sive in time and resources, and lead to poor
reliability and a lack of trust and conﬂicts;25
3. People may oppose the initiative or behave
in a self-interested manner, increasing the
costs to manage the rest of the process or
leading to suboptimal decisions;26
4. Voluntary participation can be seen as a
free and inﬁnite resource, and local people
might be expected to do for free what
experts are generally paid for;51
5. If programmes rely on short-term funding
and depend entirely on the enthusiasm of
individuals, they may not be sustainable in
the long-term.52
There is also the risk that PPI might be used
as an excuse for not doing more rigorous
evaluation, or simply to obtain consent and
legitimacy.
Towards a framework for evaluating costs
of PPI
Current shortcomings
When evaluating the impacts of PPI, we cannot
forget that there are many opportunity costs
linked to it. Many PPI practitioners are scepti-
cal of any attempt at ‘valuing’ participation
practice and see economic or monetary analysis
of the costs and beneﬁts as reductionist or sim-
plistic. When economic analysis of patient
involvement activities is performed, recording
of costs and beneﬁts is fragmented.53 Insuﬃ-
cient resources are allocated for monitoring and
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evaluation at the outset and costs are diﬃcult to
measure retrospectively. Where eﬀorts are
made, it is often diﬃcult to pinpoint the costs of
speciﬁc PPI activities. The costs of PPI are typi-
cally funded from various budgets or badly
recorded, making it diﬃcult to identify the real
aggregate cost. The iterative nature of PPI also
makes economic analysis diﬃcult, with costs
incurred at diﬀerent points in time. The nature
of participatory activity may change in the light
of experience but initial allocated budgets used
to estimate cost may not reﬂect the ﬁnal
resource use. Costs may be ‘hidden’ by practi-
tioners wanting to invest more in the process by
ﬁnding resources from other budgets. Consul-
tants supporting PPI exercises may not be will-
ing to share cost data due to commercial
conﬁdentiality. In the absence of reliable histori-
cal data and a clear benchmark, managers may
be reluctant to expose themselves to perfor-
mance management, creating a disincentive for
data collection. Finally, where costs are
recorded, it is most likely to be the cost to the
commissioning organization, with costs to par-
ticipants rarely addressed.
While traditional health economics
approaches are inappropriate for PPI, it is
important to gather improved data collection
on both the costs and beneﬁts of PPI.
Although the relationship between costs and
outcomes cannot be expressed in a neat equa-
tion, it is still important to document and com-
pare them to help make costs more transparent
and clarify what the investment in PPI delivers.
This will help provide a clearer picture for
decision makers, enabling them to better assess
the cost-eﬀectiveness or ‘business case’ for PPI
and whether and how a PPI initiative beneﬁts
patients. This should also help organizations
set appropriate budgets to fund PPI activities.
A framework for recording costs
Whose perspective?
Economic evaluation can be undertaken from
a number of diﬀerent perspectives – the per-
spective of the organization providing the ser-
vice or intervention, the patients receiving it,
both of these, or wider society. The choice of
perspective determines what costs and eﬀects
to count and how to measure and value them
(for example, from an organizational perspec-
tive, it would be necessary to include the costs
borne by the organization for setting up and
managing participatory events; from a patient’s
perspective, the travel expenditure and the time
spent to attend the same events would need to
be included).27,30 As NHS organizations pay
for PPI activities in the UK, recording costs
from their perspective is clearly important. But
excluding patients’ costs risks underestimating
the value of patient involvement. An over-reli-
ance on the enthusiasm and goodwill of indi-
viduals risks long-term sustainability of PPI
initiatives.52
A comprehensive societal perspective should
incorporate all costs and beneﬁts regardless of
who experiences them. It includes all health-
care costs, social services costs, wider spillover
costs both across the economy and costs that
are incurred by the patient and family. This is
important for recognizing the distributional
impacts of participation and better understand-
ing of relationship between participation and
equity/social justice.
Proposed framework for more eﬀectively capture
costs
Through the literature on the costs of partici-
pation, we can identify direct monetary costs,
non-monetary costs and risks that in many
cases can become a cost for the project man-
agement. The direct monetary costs include all
the costs that can be directly attributed to
events and activities of public involvement.
These costs include paid staﬀ time, staﬀ
expenses, external staﬀ/consultants, fees to par-
ticipants, participants’ expenses, training for
staﬀ and participants, administration, venue
hire, other event costs, monitoring and evalua-
tion fees.54 Non-monetary costs include the
time contributed by participants, including time
from other work or activities.
A proposed framework for comprehensive
and consistent data collection is illustrated in
Table 2. This illustrates the range of data items
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that will be used to assess cost from both an
organizational and patient perspective. In
Table 3, a template for data collection and cost
item for PPI activities is proposed.
Conclusions
Patient and public involvement in health-care
decision making is an essential activity if new
services are to be designed in a way that ensures
they secure widespread legitimacy. While atten-
tion has been paid to how to engage stakehold-
ers and manage the PPI process, only limited
attention has been paid to the eﬀectiveness of
PPI. Eﬀectiveness is not simply a measure of
the number of patients involved in a PPI exer-
cise; it must also take into account the cost
implications of these activities.
While PPI may indeed result in important
beneﬁts, it also consumes resources, both in
monetary and non-monetary terms, making it
all the more important to evaluate its eﬀective-
ness in economic terms and provide benchmarks
against which future activity can be tested.
However, the lack of an appropriate analytical
framework represents a serious constraint for a
complete economic evaluation of PPI.
The framework proposed in this article aims
to help make more explicit the variety of costs
that are typically ‘hidden’ or ignored, particu-
larly costs to patients. It therefore forms the
basis for a comprehensive but straightforward
and pragmatic way for health service organiza-
tions, patient groups and other stakeholders to
bring greater clarity to their costs. Greater clar-
ity on both costs and beneﬁts of diﬀerent
approaches to PPI will enable decision makers
to more clearly assess the ‘business case’ for
PPI from a more informed perspective.
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Table 2 Cost assessment and collection
The assessment of the costs involved in the participatory
activity should follow a deﬁned path
• Identiﬁcation of the planned activities: all the activities
involved in the participation process should be identiﬁed
and tracked (set up, design, implementation, meetings,
advertising, consultation etc);
• Identiﬁcation of resources involved in each activity: staff,
patients, materials, other cost items;
• Relevant information about activities should be recorded
in a spreadsheet or in a diary to keep track of what has
been done, who was involved, when, for how long;
• A reliable measure should be identiﬁed to assess the
cost of each item (e.g. time spent by staff for each activ-
ity, travel time for travel expenses);
• Data collection: quantity and value of each item should
be collected through direct measurement (where
possible), interviews, time sheet, administrative records,
diaries;
• Quantity of resources used should be listed;
• Unitary cost for each item should be assessed;
• Total cost for each item is given by the quantity for the
unitary cost;
• Total cost of the participation is the sum of the cost of
each activity.
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